SCHEMBL13623196

SCHEMBL13623196

CC(=O)N(Cc1cccc(NC(=O)OC(C)(C)C)c1)Cc1cccc(Nc2nc(Cl)ncc2Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.45
STK17B O94768 1/20 0.45
STK17A Q9UEE5 1/20 0.45
MET P08581 1/20 0.43
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
BRD4 O60885 2/20 0.40
SIRT2 Q8IXJ6 1/20 0.40
CDK1 P06493 1/20 0.40
EGFR P00533 5/20 0.40
SRC P12931 1/20 0.40
BCL6 P41182 1/20 0.39
BTK Q06187 2/20 0.39
MAPK3 P27361 1/20 0.38
CTSL P07711 1/20 0.38
CTSC P53634 1/20 0.38
CCNT1 O60563 1/20 0.38
CCNK O75909 1/20 0.38
CYP3A4 P08684 1/20 0.38
CCND3 P30281 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13623131 0.87 SYK (0.50) SYKSTK17BSTK17AMETAURKA
SCHEMBL4348211 0.87 BTK (0.38) EGFRBTKCTSLCTSCCCNT1
SCHEMBL4180112 0.87 SYK (0.57) SYKSTK17BSTK17AMETBRD4
SCHEMBL13623129 0.86 SYK (0.47) SYKSTK17BSTK17AMETAURKA
SCHEMBL13623118 0.85 AURKA (0.50) SYKSTK17BSTK17AMETAURKA
SCHEMBL13623023 0.85 MET (0.49) SYKSTK17BSTK17AMETAURKA
SCHEMBL1025373 0.84 STK17B (0.52) SYKSTK17BSTK17AMETAURKA
SCHEMBL13623085 0.84 SYK (0.45) SYKSTK17BSTK17AMETAURKA
SCHEMBL13623203 0.84 MET (0.48) SYKSTK17BSTK17AMETAURKA
Trifluoroacetic Acid SCHEMBL4348204 0.84 CTSC (0.41) EGFRBCL6BTKCTSLCTSC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK SYK 46/4885STK17B 139/4885STK17A 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.